Table 3 Differences in characteristics between patients with no morning and night symptoms, only morning or night symptoms and patients with both morning and night symptoms

From: Morning and night symptoms in primary care COPD patients: a cross-sectional and longitudinal study. An UNLOCK study from the IPCRG

  No morning/night symptomsOnly morning symptoms, no night symptomsOnly night symptoms, no morning symptomsMorning and night symptomsP value
  n= 908n=444n=164n=715 
Characteristics
 AgeMean (s.d.)65.9 (0.4)63.2 (0.6)64.8 (0.9)65.4 (0.6)<0.000
 Age of onsetMean (s.d.)52.9 (0.8)50.1 (1.2)54.9 (1.4)53.8 (1.1)NS
 Malen (%)495 (58.9)188 (56.5)74 (54.4)203 (57.5)NS
 ExacerbationsMean (s.d.)0.6 (1.0)0.8 (1.2)0.6 (0.9)0.9 (1.0)<0.000
 FEV1/FVC post-proportion predictedn (%)57.3 (10.7)54.2 (11.4)55.9 (10.6)55.7 (11.1)<0.000
 FEV1 post-proportion predictedn (%)72.1 (17.4)66.6 (17.8)69.7 (19.2)67.2 (18.2)<0.000
Smoking
 Current smokern (%)316 (37.6)194 (58.3)71 (52.2)203 (57.5)<0.000
 Never smokern (%)29 (3.5)7 (2.1)3 (2.2)16 (4.5) 
 Quit 12 months agon (%)493 (58.7)131 (39.3)62 (45.6)134 (38.0) 
Clinical COPD Questionnaire(CCQ)
 Subscale functional statusMean (s.d.)0.6 (0.0)0.9 (0.0)0.9 (0.1)1.0 (0.0)<0.000
 Subscale mental statusMean (s.d.)0.1 (0.0)0.2 (0.0)0.3 (0.1)0.5 (0.0)<0.000
 Subscale symptom statusMean (s.d.)1.3 (0.0)1.8 (0.0)1.8 (0.1)2.2 (0.0)<0.000
 Total scoreMean (s.d.)0.8 (0.0)1.1 (0.0)1.1 (0.0)1.4 (0.0)<0.000
Symptoms
 Sputum aMean (s.d.)1.1 (0.0)1.9 (0.1)1.7 (0.1)2.5 (0.1)<0.000
 Wheezing bMean (s.d.)0.8 (0.0)1.3 (0.1)1.3 (0.1)1.9 (0.1)<0.000
 Exacerbations cMean (s.d.)0.6 (1.0)0.8 (1.2)0.6 (0.9)0.9 (1.0)<0.000
GOLD Stage
 1n (%)299 (35.6)50 (36.8)50 (36.8)121 (34.3)<0.000
 2n (%)470 (56.0)68 (50.0)68 (50.0)189 (53.5) 
 3n (%)68 (8.1)17 (12.5)17 (12.5)41 (11.6) 
 4n (%)3 (0.4)1 (0.7)1 (0.7)2 (0.6) 
 An (%)458 (54.5)84 (25.2)36 (26.5)52 (14.7)<0.000
 Bn (%)210 (25.0)130 (39.0)62 (45.6)182 (51.6) 
 Cn (%)104 (12.4)40 (12.0)14 (10.3)17 (4.8) 
 Dn (%)67 (8.0)79 (23.7)24 (17.6)102 (28.9) 
Medication
 No medicationn (%)387 (42.6)164 (36.9)80 (48.8)287 (40.1)0.06
 Short-acting bronchodilatorsn (%)90 (9.9)77 (17.3)24 (14.6)145 (20.3)<0.000
 Inhaled corticosteroidsn (%)68 (7.5)39 (8.8)11 (6.7)52 (7.3)NS
 Leukotriene antagonistsn (%)3 (0.3)1 (0.2)0 (0.0)1 (0.1)NS
 Short-acting bronchodilator and anticholinergicsn (%)2 (0.2)0 (0.0)0 (0.0)0 (0.0)NS
 Long-acting bronchodilatorsn (%)26 (2.9)25 (5.6)4 (2.4)30 (4.2)0.074
 Combination inhaled corticosteroids and long-acting bronchodilatorsn (%)277 (30.5)137 (30.9)50 (30.5)206 (28.8)NS
 Long-acting muscarinic antagonistsn (%)223 (24.6)97 (21.8)23 (14.0)144 (20.1)0.012
 Short-acting muscarinic antagonistsn (%)67 (7.4)32(7.2)12(7.3)1 (0.1)NS
 Oral corticosteroidsn (%)0 (0.0)2 (0.5)0 (0.0)57 (8.0)NS
  1. The total number of patients in this table is 2,231, as 38 patients did not fill in the ACQ.
  2. Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, Global initiative for chronic obstructive disease; NS, not significant.
  3. aCCQ question 6.
  4. bACQ question 5.
  5. cDefined as having used antibiotics or oral corticosteroids in the past 12 months for respiratory complaints.